Beta-Blocker Use and Outcomes in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fraction
In this observational analysis of non-randomized BB treatment, there was no suggestion that BB use was associated with worse HF outcomes in HFmrEF/HFpEF, even after extensive adjustment for other prognostic variables.
Authors
- Shingo Matsumoto (ORCID: https://orcid.org/0000-0003-2698-0839)
- Inder S. Anand (ORCID: https://orcid.org/0000-0003-1308-4963)
- Pardeep S. Jhund (ORCID: https://orcid.org/0000-0003-4306-5317)
- John J.V. McMurray (ORCID: https://orcid.org/0000-0002-6317-3975)
- Margaret M. Redfield (ORCID: https://orcid.org/0000-0002-0946-7518)
- Rudolf A. de Boer (ORCID: https://orcid.org/0000-0002-4775-9140)
- Alasdair Henderson (ORCID: https://orcid.org/0000-0002-8903-4906)
- Felipe A. Martínez (ORCID: https://orcid.org/0000-0002-5836-972X)
- Faiez M. Zannad (ORCID: https://orcid.org/0000-0001-7456-1570)
- Milton Packer (ORCID: https://orcid.org/0000-0003-1828-2387)
- Michael R. Zile (ORCID: https://orcid.org/0000-0001-7076-221X)
- Muthiah Vaduganathan (ORCID: https://orcid.org/0000-0003-0885-1953)
- Ross T. Campbell (ORCID: https://orcid.org/0000-0002-0050-2129)
- Toru Kondo (ORCID: https://orcid.org/0000-0001-6853-7574)
- Mingming Yang (ORCID: https://orcid.org/0000-0003-4484-0979)
- Aldo P. Maggioni (ORCID: https://orcid.org/0000-0003-2764-6779)
- Akshay S. Desai (ORCID: https://orcid.org/0000-0002-1443-0701)
- Li Shen (ORCID: https://orcid.org/0009-0002-0620-9887)
- Dirk Jan van Veldhuisen
- Scott Solomon
- Jean L. Rouleau (ORCID: https://orcid.org/0009-0004-0592-8091)
- Carolyn S.P. Lam
Institutions
- Brigham and Women's Hospital (US)
- Toho University (JP)
- University of Minnesota (US)
- Mayo Clinic (US)
- University Medical Center Groningen (NL)
- Medical University of South Carolina (US)
- Inserm (FR)
- Hangzhou Normal University (CN)
- National University of Singapore (SG)
- University of Groningen (NL)
- Montreal Heart Institute (CA)
- Erasmus MC (NL)
- Baylor University Medical Center (US)
- WinnMed (US)
- British Heart Foundation (GB)
- Associazione Nazionale Medici Cardiologi Ospedalieri (IT)
- Zhongda Hospital Southeast University (CN)
- National University Heart Centre Singapore (SG)
- Health Care Foundation (CA)
- Mayo Clinic in Arizona (US)
- Ralph H. Johnson VA Medical Center (US)
- Minneapolis VA Medical Center (US)
- Mayo Clinic in Florida (US)
- National Heart Centre Singapore (SG)
- Erasmus MC Cancer Institute (NL)
- Nagoya University (JP)
- Cordoba University (US)
- Université de Montréal (CA)
- University of Glasgow (GB)
- Université de Lorraine (FR)
Publication Details
- Journal
- European Journal of Heart Failure
- Published
- 2024-08-31
- DOI
- https://doi.org/10.1002/ejhf.3383
- Citations
- 15
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.03
Funders
- Amgen
- Eli Lilly and Company
- AstraZeneca
- Bayer
- Sanofi
- Gilead Sciences
- Alnylam Pharmaceuticals
- Celladon Corporation
- Regeneron Pharmaceuticals
- Cytokinetics
- Sarepta Therapeutics
- MyoKardia
- Moderna
- University of Glasgow
- Daiichi-Sankyo
- Sun Pharma
- Intas Pharmaceuticals
- National Institutes of Health
- Sanofi Pasteur
- American Regent
- Respicardia